Evaluation of the pharmacokinetics, dosimetry, and therapeutic efficacy for the α-particle-emitting transarterial radioembolization (αTARE) agent [225Ac]Ac-DOTA-TDA-Lipiodol® against hepatic tumors

EJNMMI Radiopharmacy and Chemistry

Table 2 Mean absorbed dose coefficients, (d) [mGy/kBq], for [²²⁵Ac]Ac-DOTA-TDA-Lipiodol^® and the decay daughters francium-221 (including astatine-217) and bismuth-213 (including polonium-213) in female tumor-bearing mice and non-tumor bearing male Sprague–Dawley rats

Organs/Tissues	[²²⁵Ac]Ac-DOTA-TDA-Lipiodol^® d [mGy/kBq]	Francium-221 d [mGy/kBq]	Bismuth-213 d [mGy/kBq]	Total d [mGy/kBq]
Female mice
Blood	10.3	10.9	6.7	28.0
Kidneys	97.4	121.6	191.2	410
Liver	1213	− 44.5	− 102.8	1066
Tumor	5549	− 962	− 547	4040
Male rats
Blood	0.38	0.25	0.19	0.82
L. kidney	8.3	1.5	5.2	14.9
L. lateral liver lobe	27.7	− 4.0	− 3.6	20.1

Negative numbers mean the daughters relocate away from the organ/tissue, thereby reducing the absorbed dose
Positive numbers mean the daughters relocate and accumulate within this organ/tissue, thereby increasing the absorbed dose